checkAd
    Startseite > Aktien > Revance Therapeutics > Nachrichten
    Revance Therapeutics Aktie
    2,5400
     
    EUR
    +1,60 %
    +0,0400 EUR
    Letzter Kurs 10:24:24 Tradegate
    2,4800
     
    EUR
    2.440 STK
    Geldkurs 11:47:05
    2,5400
     
    EUR
    1.566 STK
    Briefkurs 11:47:05
    ISIN: US7613301099 · WKN: A1XD3D · SYM: RTI · USA

    Neueste Nachrichten

    Revance to Participate in Upcoming Investor Conferences
    28.05.24 · Business Wire (engl.) · Revance Therapeutics
    Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update
    09.05.24 · Business Wire (engl.) · Revance Therapeutics
    Revance to Release First Quarter 2024 Financial Results on Thursday, May 9, 2024
    02.05.24 · Business Wire (engl.) · Revance Therapeutics
    Revance to Present New DAXXIFY Data at the American Academy of Neurology 2024 Annual Meeting
    12.04.24 · Business Wire (engl.) · Revance Therapeutics
    Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    27.03.24 · Business Wire (engl.) · Revance Therapeutics
    Revance Announces Pricing of $100.0 Million Public Offering of Common Stock
    04.03.24 · Business Wire (engl.) · Revance Therapeutics
    Revance Announces Proposed Public Offering of Common Stock
    04.03.24 · Business Wire (engl.) · Revance Therapeutics
    Revance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update
    28.02.24 · Business Wire (engl.) · Revance Therapeutics
    Revance to Release Fourth Quarter and Full Year 2023 Financial Results on Wednesday February 28, 2024
    21.02.24 · Business Wire (engl.) · Revance Therapeutics
    Revance to Participate in Upcoming Investor Conferences
    21.02.24 · Business Wire (engl.) · Revance Therapeutics
    Revance Receives Permanent J-Code for DAXXIFY and Announces Publication of DAXXIFY Pivotal Study (ASPEN-1) Results in Neurology
    02.02.24 · Business Wire (engl.) · Revance Therapeutics
    Revance to Participate in the Guggenheim 6th Annual Biotechnology Conference
    01.02.24 · Business Wire (engl.) · Revance Therapeutics